Pharmaceutical Executive February 5, 2024
The era of big pharma as product-first companies must end, as services become the larger priority.
Every day, new advancements are being made in the development of personalized medicines. Just recently, the FDA approved a gene editing therapy for treating sickle cell.1 Since 2020, personalized medicines have made up more than a third of new molecular entities approved by the FDA.2 And new discoveries are showing how promising the future of this field can be—like a gene therapy that has allowed an 11-year-old boy to hear for the first time.
All sorts of developments in the field lie ahead. In fact, Mark Melton, vice president of the clinical trial execution platform Slope, predicts...
Today's Sponsors
Today's Sponsor